Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473518 | 0.90 | KDM4E (0.51) | KMT2AMEN1GPR119ESR2NR1H2 | |
| SCHEMBL14154600 | 0.89 | GPR119 (0.55) | KMT2AMEN1GPR119ESR2NR1H2 | |
| SCHEMBL31705318 | 0.88 | KMT2A (0.47) | KMT2AMEN1GPR119ESR2NR1H2 | |
| SCHEMBL14338856 | 0.87 | NR1H2 (0.45) | KMT2AMEN1GPR119ESR2NR1H2 | |
| SCHEMBL4929719 | 0.86 | KMT2A (0.62) | KMT2AMEN1GPR119KDM4ESMN1; SMN2 | |
| SCHEMBL19598956 | 0.86 | GPR119 (0.52) | GPR119 | |
| SCHEMBL4929304 | 0.85 | KMT2A (0.60) | KMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL14720577 | 0.84 | ATM (0.49) | KMT2AMEN1GPR119ESR2LMNA | |
| SCHEMBL1602493 | 0.84 | GPR119 (0.50) | GPR119 | |
| SCHEMBL4931097 | 0.83 | SMN1; SMN2 (0.55) | KMT2AMEN1GPR119KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079735-B1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | ASTRAZENECA AB (SE) | 2012-02-01 | — | — | EP | claimed |
| JP-4668346-B2 | — | — | 2011-04-13 | — | — | JP | claimed |
| US-20100160374-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | claimed |
| JP-2010506910-A | — | — | 2010-03-04 | — | — | JP | claimed |
| EP-2079735-A1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | AstraZeneca AB (SE) | 2009-07-22 | — | — | EP | claimed |
| US-20080182875-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | claimed |
| WO-2008048171-A1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | WO | claimed |
| US-20170327491-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES AND THEIR USE AS DELTA OPOID RECEPTOR AGNISTS | PHARMNOVO AB (SE) | 2017-11-16 | — | — | US | disclosed |
| US-20170327491-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES AND THEIR USE AS DELTA OPOID RECEPTOR AGNISTS | PHARMNOVO AB (SE) | 2017-11-16 | — | — | US | disclosed |
| WO-2016099394-A1 | NOVEL SELECTIVE DELTA-OPIOID RECEPTOR AGONISTS USEFUL FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | PHARMNOVO AB (SE) | 2016-06-23 | — | — | WO | disclosed |
| EP-2079735-B1 | N- (2 -HYDROXYETHYL) -N-METHYL- 4- (QUINOLIN- 8-YL (1- (THIAZOL-4- YLMETHYL) PIPERIDIN- 4 -YLIDENE) METHYL) BENZAMIDE, THE PROCESS OF MAKING IT AS WELL AS ITS USE FOR THE TREATMENT OF PAIN, ANXIETY AND DEPRESSION. | ASTRAZENECA AB (SE) | 2012-02-01 | — | — | EP | disclosed |
| US-7977355-B2 | N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-20110082173-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
| US-20030149023-A1 | Novel compounds with analgesic effect | ASTRAZENECA CANADA INC. | 2003-08-07 | — | — | US | disclosed |
| EP-1286986-A1 | QUINOLINYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2002094810-A1 | 4-(PHENYL-PIPERIDIN-4-YLIDENE-METHYL)-BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2002-11-28 | — | — | WO | disclosed |
| US-6455545-B2 | GASTROINTESTINAL DISORDERS | ASTRAZENECA CANADA INC. (CA) | 2002-09-24 | — | — | US | disclosed |
| WO-2001074806-A1 | QUINOLINYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-10-11 | — | — | WO | disclosed |
| US-20010021715-A1 | Novel compounds with analgesic effect | ASTRA PHARMA INC. | 2001-09-13 | — | — | US | disclosed |
| US-6187792-B1 | PIPERIDIN-4-METHYLIDENE-4-BENZAMIDE DERIVATIVES; OPOID RECEPTOR ANTAGONISTS; CANCER PAIN | ASTRA PHARMA INC. (CA) | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327491-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES AND THEIR USE AS DELTA OPOID RECEPTOR AGNISTS | OPRD1, OPRM1, OPRK1 | KMT2A 3532/4885MEN1 4860/4885GPR119 371/4885 |
| US-20010021715-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | KMT2A 4601/4885MEN1 4421/4885GPR119 648/4885 |
| US-20080182875-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2C8, UGT1A8 | KMT2A 63/4885MEN1 2216/4885GPR119 2827/4885 |
| US-20100160374-A1 | N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2C8, UGT1A8 | KMT2A 63/4885MEN1 2216/4885GPR119 2827/4885 |
| US-20030149023-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | KMT2A 4601/4885MEN1 4421/4885GPR119 648/4885 |
| US-20110082173-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | OPRM1, OPRD1, QDPR | KMT2A 1165/4885MEN1 2455/4885GPR119 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.